Domestic innovative pharmaceutical companies' globalization progress continues to accelerate, with the Hong Kong-listed Innovative Drug ETF Invesco ( 513780 ) rising strongly by over 5%.

NightAirdropper · 2026-04-03T00:47:41+00:00

On April 1, 2026, the Hong Kong Stock Connect Innovation Drug ETF (Invesco) rose by 5.58%, with many constituent stocks experiencing significant gains. China's innovation drug licensing transaction volume exceeded $60 billion, and the market is optimistic about the enhancement of Chinese pharmaceutical companies' global competitiveness. Institutional analysts indicate that supportive policies and the release of global data are expected to help promote the development of the innovation drug industry.

NightAirdropper

2026-04-03 00:47:41

Abstract generation in progress

On April 1, 2026, during the intraday session, the innovative drug concept remained active. By the midday close, the Hang Seng innovative drug ETF from Invesco (513780) was up 5.58%. Among constituent stocks, Lepu Biotech-B rose 15.92%, Rongchang Biotech rose 13.26%, Junshi Biosciences rose 10.54%, and shares such as Q&K and Zhaoyang New Medicine also moved higher.

【Domestically, the globalization progress of innovative drug companies continues to accelerate】

In the first three months of 2026, the total value of China’s innovative drug external licensing transactions has already exceeded $60 billion, approaching about half of 2025 for the full year. The participation and recognition of China’s innovative drug assets in the global transaction ecosystem have increased significantly.

Institutional analysts believe that the NMPA’s launch of the three-year “Spring Rain Action” for the transformation of clinical innovation achievements of medical devices will further strengthen support for the industrialization and implementation of innovative achievements. Combined with the upcoming 2026 AACR annual meeting, expectations for global data readouts from Chinese companies in cutting-edge areas such as ADCs, bispecific antibodies, small molecules, and CAR-T are heating up. This could help strengthen the market’s recognition of China’s innovative drugs’ global competitiveness.

The Invesco Hang Seng innovative drug ETF (513780) can be traded on a T+0 basis. The index includes Hong Kong innovative drug leaders such as WuXi Biologics, Innovent Biologics, and BeiGene. With bio-products + chemical pharmaceutical weights accounting for more than 85%, it helps support efficient, high-turnover layout of the high-elasticity Hong Kong innovative drug sector. The fund also sets up an off-exchange linked fund (Class A: 023597, Class C: 023598). Off-exchange investors may keep an eye on it.

The data above comes from Wind and public information, as of 2026/3/31. Risk warning: The market involves risk; investment requires caution!

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.